Clinical TrialsSearch results
Number of results: 213
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Other
- Research on the usefulness of pneumococcal polysaccharide vaccine for elderly in the nursing home
- Pneumonia in the nursing home
- Research Institute for Microbial Diseases, Osaka University
- 2009-07-17
Other
- Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease
- Kawasaki disease
- Randomized controlled trial to Assess Immunoglobulin plus Steroid Efficacy for Kawasaki disease (RAISE) Study Group
- 2008-01-27
Other
- Randomized clinical trial about the period of antimicrobial prophylaxis administration in hepatocellular carcinoma surgery
- Patients undergoing elective hepatocellular carcinoma surgery
- Randomized clinical trial committee, Japan Society for Surgical Infection
- 2009-12-09
Other
- Primary prevention of cerebrovascular and cardiovascular events with an oral antidiabetic agent in patients with type 2 diabetes at high risk for cerebral infarction
- Type 2 Diabetes
- PROFIT-J Study Steering Committee
- 2007-10-09
Other
- Post-marketing study of cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison with Aspirin
- Patients with cerebral infarction (excluding cardiogenic cerebral embolism)
- Otsuka Pharmaceutical Co., Ltd.
- 2005-09-13
Recruiting
- Atopic Dermatitis: A Study of Upadacitinib in Adult Subjects with Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)
- Atopic Dermatitis
- Otani Tetsuya
- 2024-06-21
Recruiting
- [M23-784] A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
- Crohn's Disease
- Otani Tetsuya
- 2024-03-11
Not yet recruiting
- A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo
- NonSegmental Vitiligo
- Ono Shintaro
- 2024-06-14
Other
- A study on the immune response and safety of a vaccine against respiratory syncytial virus given to adults 50-59 years of age, including adults at increased risk of respiratory syncytial virus lower respiratory tract disease, compared to older adults 60 years of age and above.
- RSV infection
- Okawa Yasutoshi
- 2022-11-16
Other
- Outcome Assessment using SF-36 v2 in Stroke Patient Study
- Brain infarction
- OASIS STUDY Research Group
- 2008-05-31